Jane Fitch

Contact Information:
Jane Fitch


Fitch, Jane M.D. (HSC)

Department of:

College Of Medicine/Anesthesiology -Professor & Chair, John L. Plewes, Chair

Center of:


University of Texas Houston   Medical Degree   1988
Executive Leadership in Academic Medicine (ELAM) MCP Hahneman University, Philadelphia, PA   Fellowship   2001
UWMC, Seattle, WA   Fellowship, Cardiothoracic and Vascular Anesthesiology   1993
UWMC, Seattle, WA   Residency   1992
St. Joseph's Hospital, Houston, TX   Transitional Internship   1989

Professional Interest/Expertise/Specializations:
Jane C.K. Fitch, M.D. is Professor and Chair of the Department of Anesthesiology at the University of Oklahoma Health Sciences Center in Oklahoma City, and has served in this position since November 12, 2001. She received her medical education at the University of Texas Health Science Center in Houston, Texas, where she graduated Alpha Omega Alpha; completed internship training at St. Joseph's Hospital in Houston, followed by a residency and fellowship in cardiovascular and thoracic anesthesiology at the University of Washington in Seattle. She served as an assistant professor and fellowship director at Yale University School of Medicine and Associate Operating Room Manager at Yale New Haven Hospital in New Haven, Connecticut. She served as Division Chief and Interim Vice Chair at Baylor College of Medicine in Houston, Texas. Clinically she is a board-certified adult cardiovascular & thoracic anesthesiologist. Prior to her medial career, Dr. Fitch worked as an ICU nurse, followed by nurse anesthesia. Dr. Fitch holds several leadership positions within her college, faculty practice plan and hospital. She has held, and currently holds, several state and national organized medicine positions and is currently serving as the 1st Vice President for the American Society of Anesthesiologists.


ASA 1st Vice President
Advocacy for the patient

Research Projects:

A Double-Blind Placebo-Controlled Ascending Dose Study of E5564, a Lipid A Antagonist, in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass Principal Investigator, 2003, $316,940, Contract.
Phase II Multi-Center, Placebo-Controlled, Randomized, Stratified, Double-Blind, Dosing Regimen Optimazation and Dose Escalation Study to Evaluate the Safety, Toleration and Clinical Pharmacology of Zoniporide Asministered for up to 7 days to Subjects Undergoing Coronary Artery Bypass Graft (CABG) Surgery, Pfizer, Inc., Principal Investigator, 2001, $200,00, Contract.
A Phase II Randomized, Double-Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Hemolink (o-reffinose cross-liked human hemoglobin) in Patients Undergoing Primary Coronary Artery Bypass Grafting Surgery, Hempsol, Inc., Principal Investigator, 2000, $140,100.00, Contract.
A Phase III SIngle-Blind, Randomized, Parallel-Group, Multicenter, Controlled Study of the Effectiveness of 2.7 gPFC/kg of Perflubron-based Emulsion (AF0144) to Augment Intraoperative Autologous Donation and Avoid Transfussion of Allogeneic Red Blood Cells in Patients Undergoing Primary Coronary Bypass Graft Surgery under Cardiopulmonary Bypass, Alliance Pharmaceuticals, PI,1999, $162,000 Contract
Phase I Study of h5G1.1-scFv in Patients Undergoing Cardiopulmonary Bypass, Alexion Pharmaceuticals Inc., Co-Investigator, 1996-97, $230,000.00, Contract.

Selected Publications:

Full-Dose Aprotinin Use in Coronary Artery Bypass Graft Surgery: An Analysis of Perioperative Pharmacotherapy and Patient Outcomes
2006    Royston, D. Levy, J. Fitch, J., Dietrich, W., Body, S., Murkin, J., Spiess, B.D., Nadal
Anesthesia & Analgesia, Vol 103, No 5, 1082-1088
Antithrombin Reduces Monocyte and Neutrophil CD 11b Upegulation in Addition to Blocking Platelet Activation During Extracorporeal Circulation.
2006    Rinder, C.S., Rinder, H.M., Smith, M.J., Tracey, J.B., Fitch, J.C.K, Chandler, W.L., Smith, B.R.
Transfusion, Vol 45, No 7 pg. 1130-1137
Pharmacologic C5-Complement Suppression Reduces Blood Loss During On-Pump Cardiac Surgery.
2005    Chen, J.C., Rollins, S.A., Sherman, S.K., Boyce, S., Allen, K., Wallace, A., Malloy, K.J., Eng, J.S., Colman, R.W., Fitch, J.C.K.,
Journal of Cardiac Surgery Vol 20, No 1, 35-41
Impact of Pexelizumab, a Recombinant, Humanized, Single-Chain, Anti-C5 Complement Antibody, on Total Mortality and Adverse Cardiovascular Outcomes in Cardiac Surgical Patients Undergoing Cardiopulmonary Bypass.
2004    Shernan, S.K., Fitch, J.C.K., Nussmeier, N.A., Chen, J.C., Rollins, S.A., Mojcik, C.F., Malloy, K.J. Todaro, T.G., Filloon, T., Boyce, S.W., Gangahar, D.M., Goldberg, M., Saidman, L.J., Mangano, D.T.
Ann of Thor Surg. Vol 77, No 3 pg. 942-949
Preliminary Effects of the Effects of Complement Supression with Pexelizumab on Neurocognitive Decline After Coronary Artery Bypass Graft Surgery.
2004    Matthew, J.P., Shernan, S.K. , W.D., Fitch, J.C.K., Chen, J.C., Bell, L., Newman, M.F.
Stroke. Vol 35 No 10, pg 2335-2339
Platelet Tranfusions during Cononary Artery Bypass Graft Surgery are Associated with Serious Adverse Outcomes.
2004    Spiess, B.D., Royston, D., Levy, J., Fitch, J., Dietrich, W., Body, S., Murkin, J., Nadal, A.
Transfusion. Vol 44, pg 1143-1148
Increased CK-MB Predicts Postoperative Mortality after Cardiac Surgery Independent of New Q Waves.
2004    Ramsay, J., Shernan, S., Fitch, J., Finnegan, P., Todaro, T., Filloon, T., Nussmeier, N.A.
JTCVS. Vol 129, No 2, pg 300-306
Segmental Vascular Resistance Following Mild Controlled Cortical Impact Injury in the Rat
2003    Golding, E.M., Robertson, C.S., Fitch, J.C.K., Goodman, J.C., Bryan, R.M.
J of Cerebral Flow and Metabolism Vol 23, No 2, pg. 210-218
Current Transfusion Practices of Members of the American Society of Anesthesiologists.
2003    Nuttall, G.A.., Stehling, L.c., Beighley, C.M., Faust, R.J., ASA Committee on Transfusion Medicine
Anesthsiology Vol 99, No 6 pg. 1433-1443
Transesophageal Echocardiography Interpretations: A Comparative ANalysis Between Cardiac Anesthesiologiusts and Primary Echocardiographers
2002    Matthew, J.P., Fontes, M., Garwood, S., Davis, E.,White, W.D., McCloskey, G., Fitch, J.C.K., Afifi, S., Lee, D.L., Kraker, P., Rafferty, T.D., Barash, P.G., Gilliam, L., Prokop, E.
Anesth & Analg, Vol 94, No 2, pg. 302-309.
A Prospective, Randomized, Double-Blinded, Controlled Multi-Center Trial of Remifentanil and Fentanyl in Fast Track Cabg Surgery: Efficacy and Resource Utilization.
2001    Cheng, D.C.H., Newman, M.F., Duke, P., Wong, D.T., Finegan, B., Howie, M., Fitch, J.C.K., Hogue, C., Hillel, Z., Pierce, E., Bukenya, D.
Anesth & Analg, Vol. 92, No 5 pg. 1094-1102
Selective Blocakde of Membrane Attack Complex Formation during SImulated Extracorporeal Circulation INhibits Platelet but not Leukocyte Activation.
1999    Rinder, C.S., Rinder, H.M., Smith, M.J., Tracey, J.B., Fitch, J.C.K., Li, L.Rollins, S.A., Smith, B.R.
J Thorac & Cardiovasc Surgery. 118(3): 460-466, Sept 1999.
Point-of-care and Standard Laboratory Coagulation Testing in Cardiovascular Surgery-Balancing Reliability and Timeliness.
1999    Fitch, J.C.K., Mirto, G.P., Geary, K.L.B., Byrne, D.W., Hines, R.L.
Journal of Clin Monitoring. Vol 15 No, 3-4, pg. 197-204
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single Chain Antibody C5 Inhibitor in Patients undergoing Coronary Artery Bypass Graft Surgery utilizing Cardiopulmonary Bypass
1999    Fitch, J.C.K., Rollins, S,A,m Matis, L., Alford, B., Aranki, S., Collard, D., Dewar, M., E.efteraides, J.A., Haines, R.L., Hines, R.L., Kopf, G., Kraker, P., Li, L. O'Hara, R., Rinder, C.S., Rinder, H.M., Shaw, R., Smith, B.R., Stahl, G., Shernan, S.K.
Heparin Management Test (HMT) versus Activated Clotting Time (ACT) in Cardiovascular Surgery: Correlation with Anti-Xa Activity.
1999    Fitch, J.C.K., Geary, K.L.B., Mirto, G.B., Byrne, D.W., Hines, R.L.,
Journal of Cardiovasc and Thorac Anesth. Vol 13, No 1 pg. 53-57
A Comparison of Thromboelastography with Heparinase or Protamine Sulfate Added in-vitro during Heparinized Cardiopulmonary Bypass.
1997    Spiess, B.D., Wall, M.H., Gillies, B.S., Fitch, J.C.K., Soltow, L.O. Chandler, W.L.
Thrombosis and Haemostasis Vol 78, No. 2, pg. 820-826
Con: Heparin is Not the Best Anticoagulant for Cardiopulmonary Bypass.
1996    Fitch, J.C.K.
Jounral of Cardiothor and Casc Anesth Vol. 10 No 6, pg. 819-821
Amplification of the Imflammatory Response Adhesion Molecules Associated with Platelet/ WHite Cell Responses.
1996    Rinder, C.S. and Fitch, J.C.K.
Journal of Cardivasc Pharm Vol 27, Suppl,. 1, S6-12
Individual Variations in the Fibrinoltic Response during and after Cardiopulmonary Bypass.
1995    Chandler, W.L., Fitch, J.C.K., Wall, M.H., Verrier, E.E., Cochran, R.P., Soltpw, L.O., Spiess, B.D.
Thrombosis and Haemostasis Vol. 74 (5), pg. 1293-1297
Blockade of C5a and C5b-9 Generation Inhibits Leukocyte and Platelet Activation During Extracor[oreal Circualtion.
1995    Rinder, C.S., Rinder, H.M., Smith, B.R., Fitch, J.C.K., Tracey, J.B., Rollins, S.A.
Journal Clin Invest Vol 96, No 3, pg. 1564-1572
Keywords, Tags: